title: [Cancer chemotherapy of scirrhous type gastric cancer and evaluation of chemotherapeutic efficacy].
abstract: At present, we evaluate the effects of cancer chemotherapy for gastric cancer using for criteria the general rules for gastric cancer study. Among these rules, the draft of criteria at evaluation of chemotherapy for scirrhous type gastric cancer is mentioned. Partial response (PR) is more than 100% in the rate of enlargement of the lesion area in an upright barium-filled picture. In our 53 cases, the effective rate was 3.8% [PR 2, NC 44(MR 2), PD 7]. It is sure that enlarged cases more than 100% are effective. But, in some cases enlarged less than 100%, we found certain effects clinically. We measured the area of upright barium-filled pictures in scirrhous type gastric cancer and normal control. The average control level was 200 cm2 (160-240) and that of scirrhous type gastric cancer was 108 cm2 (40-190). Thus about half of the patients cannot become PR. In this study, we attempted to evaluate the effects by improving the X-ray findings; for example wall rigidity, thickened folds and abnormal mucosal patterns in addition to the enlargement. As a result, we recognize that it is possible to evaluate by these findings. Also, the improved cases survive for a long time compared with the unchanged ones.
authors.affiliation: Dept. of Gastroenterology, Toyosu Hospital, Showa University.
authors.forename: T
authors.initials: T
authors.lastname: Izumi
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: M
authors.initials: M
authors.lastname: Kurihara
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011859:Radiography; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D008937:Mitomycins; D003561:Cytarabine; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D005472:Fluorouracil